Viking Therapeutics and Longeveron sat at opposite ends of biotech trading in September. Viking surged after new data for its injectable GLP-1/GIP dual agonist VK2735, while Longeveron fell after a Phase 2b failure for laromestrocel in a rare congenital heart disorder.
The contrast matters beyond one month of stock performance. In a sector where the XBI declined 3.5% in September, investors still rewarded efficacy that appeared differentiated and punished a single-asset clinical setback paired with limited cash.
What moved Viking
On Sept. 22, Viking reported a Phase 1 readout designed to study VK2735 as a maintenance treatment. The candidate produced 17.7% weight loss at 21 weeks, and that efficacy held up under less frequent dosing regimens.
Truist Securities said the result met its "best-case scenario." William Blair said the data delivered a "maintenance trifecta": retained weight loss, tolerability and weekly dosing that indicates a differentiated profile. Viking's stock rose more than 30% on the news and neared $42 per share at its peak.
Viking then moved quickly to monetize that momentum. One day after the data release, the company proposed concurrent offerings of $200 million in common stock and $200 million in convertible notes. Those financings were later upsized to $275.1 million in shares, with 7.86 million sold at $35 each, and $225 million in convertible senior notes. Viking said the proceeds were mainly for VK2735 and its VK3019 amylin program.
On Sept. 28, Viking closed the financings after underwriters fully exercised their overallotment options, bringing gross proceeds to about $575 million. That capital raise diluted shareholders and pulled the stock lower in the final days of the month. By Sept. 30, Viking closed at $32.60 per share, 3.18% below where it started September.
What moved Longeveron
Longeveron dropped more than 60% in September after reporting on Sept. 16 that laromestrocel failed in a Phase 2b trial. The investigational stem cell therapy, which is the company's only clinical asset, did not improve blood flow in patients' hearts.
The setback pushed Longeveron into a strategic review. The company said it would "review all options" and reported just over $10 million in cash and cash equivalents as of June 30, with runway expected only into the fourth quarter of this year.
Longeveron said it would continue evaluating study data and communicate with the FDA about whether a path forward remains for laromestrocel in the heart condition. It also said it would keep studying the cell therapy in Alzheimer's disease, age-related frailty and pediatric dilated cardiomyopathy. As of Sept. 30, the stock was at $2.69 per share, down 60.15% from the start of the month.
The signal from both moves is straightforward: in biotech, positive obesity data can still open the capital markets even after a sharp share-price jump, while a failed study in a company with one clinical asset and a short cash runway can rapidly shift the conversation from development to survival.
